1 In-octreotide scintigraphy in patients with persistent medullary thyroid carcinoma (MTC) visualized tumors in about half of the surgically explored sites. Tumor visualization correlated with rapid tumor growth and large tumor volume as judged from calcitonin levels. The 111In concentration ratio between tumor (T) and blood (B) in surgically excised lymph node metastases of MTC showed a large variation, with low values for microscopic and high values for macroscopic metastases in individual patients. Three cases of MTC, Hurthle cell adenoma and papillary thyroid cancer are reported with preoperative scintigraphy, T/B ratios and Northern analyses of the surgical biopsies. Visualization of tumors was possible in the absence of sstr2 (the high affinity receptor for octreotide) with the exception of microscopic tumor growth. T/B values in the patient with Hurthle cell adenoma were similar to those found in the contralateral thyroid lobe with goitre. The [10] . In a previous study, we found that octreotide scintigraphy visualized large primary MTC tumors, but only half of the surgically identified neck metastases [11] .
INTRODUCTION
Neuroendocrine tumors, including medullary thyroid carcinoma (MTC)e, may express somatostatin receptors (sstr). Somatostatin and its long-acting analogue, octreotide, have been shown to inhibit incorporation of 3H-thymidine into human thyroid follicular cell lines indicating expression of sstr physiologically. Somatostatin inhibits DNA synthesis induced by thyrotropin in such cell lines [1, 2] . However, after neoplastic transformation, somatostatin analogues may induce proliferation as shown in differentiated human thyroid cancer cell lines [3] . In patients with MTC, the only effective treatment today available is surgery [4] . In cases of differentiated non-MTC tumors, distant metastases can be treated with radioiodine. Radioiodine can also be used to diagnose residual thyroid cancer in the neck as well as distant metastases. However, one third of the non-MTC tumors do not accumulate radioiodine [5] . One future aim will be to investigate expression of sstr on various types of thyroid tumors to be able to evaluate their uptake of a radiolabelled somatostatin analogue, 111In-octreotide, for diagnostic and therapeutic purposes.
a To whom all correspondence should be addressed: Ha.kan Ahlman MTC is a neuroendocrine tumor derived from thyroid C-cells. In patients with MTC, basal and stimulated serum calcitonin concentrations are sensitive tumor markers reflecting the tumor volume [6, 7] . Presence of lymph node metastases in MTC has a more serious impact on survival than in papillary thyroid carcinoma [8] . One third of the MTC patients with persistent, or recurrent, disease after primary thyroidectomy can have their calcitonin levels normalized after repeat meticulous neck operations with microdissection technique [4] . Complete work-up with ultrasound, CT, MR and bone scintigraphy has low sensitivity in the localization of new lesions [9] . The surgical results would improve if good tumor localization methods were available. Selective catheterization and calcitonin determinations can often localize tumors to a region, but not to a specific site. Scintigraphic methods utilizing 1231I or 13ll-MIBG, 201TI-chloride, 99mTc-V-DMSA or radiolabeled monoclonal antibodies against calcitonin or carcinoembronic antigen (CEA) have been of limited value so far [10] . In a previous study, we found that octreotide scintigraphy visualized large primary MTC tumors, but only half of the surgically identified neck metastases [11] .
In the present study, the IIIIn concentration ratios between tumor and blood (T/B) were determined and compared with the findings at l l In-octreotide scintigraphy in three different thyroid tumor forms (MTC, Hurthle cell adenoma and papillary thyroid cancer). In these individual patients, Northern analyses of all five sstr subtypes were also performed.
MATERIAL AND METHODS

Patients
Fifteen patients had previously been thyroidectomized for MTC. They were followed with annual tests for serum concentrations of calcitonin and CEA. At the time of the present investigation all patients had raised calcitonin concentrations indicating persistent disease. Before repeat surgery, including meticulous lymph node dissection, they underwent scintigraphy after injection of IIIn-DTPA-D-Phel-octreotide. After the operations, the II1n concentration ratios were determined between freshly harvested lymph node metastases and blood.
Three patients with different types of thyroid tumors were worked up in detail with preoperative scintigraphy and determinations of T/B ratios and sstr subtypes: Patient A had previously been subjected to thyroidectomy due to MTC and had persistent disease; Patient B had a Hurthle cell adenoma in a nodular goitre; and patient C had a papillary thyroid carcinoma with lymph node metastases. Scintigraphy
The patients received 190-350 MBq l1I1n-DTPA-D-PheI octreotide (10-20 pg) (Mallinckrodt, Petten, the Netherlands) by i.v. route. The amount of lllIn bound to octreotide was higher than 98 percent. Imaging was done 24-48 hr after injection of the radiopharmaceutical. A gamma camera (GE 400 AC/T), equipped with a medium energy parallel hole collimator and connected to a GE STARCAM computer system, was used. Data acquisition was done in a dual window setting (173 and 247 keV). Single photon emission computed tomography (SPECT) was performed in all patients (see [12] for further details).
The ratio between tumor (T) to background (Bg) uptake was calculated from preoperative scintigraphic images. A Fresh tumor specimens were rapidly frozen in liquid nitrogen. RNA was prepared by acid guanidine thiocyanate-phenol-chloroform extraction [14] . Samples of total RNA (20 ,ug) were heat-denatured and electrophoresed in a one percent agarose gel with 2.2 mol/l (Figure 1 ). Three excised lymph node metastases with macroscopic tumor growth had five-to eight-fold higher T/B ratios than normal lymph nodes, or fat tissue samples. The ratio of T/Bg uptake calculated from the preoperative scintigraphic images was much lower than the T/B ratios ( Figure 1 ). Northern analyses of a lymph node metastasis revealed expression of all receptor subtypes except sstr2 and sstr3 (Figure 4) (Figure 2 ). The ratio of TIBg uptake calculated from scintigraphy was lower with a thyroid background than with a background of adjacent tissue. A total thyroidectomy was performed with lymph node dissection. The histopathological examination demonstrated a Hurthle cell adenoma. The remaining parts of the thyroid gland revealed a nodular goitre with areas of severe sclerosis. The T/B ratio for the adenoma was higher than for the pyramidal and contralateral thyroid lobe. The lymph nodes had much lower values and had a normal histological appearance ( Figure 2 ). Northern analyses of the adenoma revealed expression of all five receptor subtypes except sstr2 (Figure 4 (Figure 3 ). The T/Bg ratio from scintigraphy did not reveal any differences between the two tumors, while the T/B ratio for the left-sided lesion was twice as high as for the right-sided lesion. A total thyroidectomy was performed with neck dissection. The histopathological examination demonstrated bilateral papillary thyroid carcinoma as well as a thyroid cyst. Of the lymph node metastases, one was clinically overt and three were microscopic. Twelve lymph nodes were tumor-free. The T/B values for the tumor were highei than the Ti/B value seen for normal thyroid tissue and for the thyroid cyst. The lymph node with macroscopic growth had similar values as two of the three nodes with microscopic growth. These values were not significantly different from the tumor-free nodes (Figure 3 ). Northern analysis of the papillary carcinoma revealed expression of all five receptor subtypes except sstr2 (Figure 4 ).
DISCUSSION
In a previous study of MTC-patients [11] with biochemically proven persistent disease, l Il In-octreotide scintigraphy visualized lymph node metastases in about half of the patients in accordance with other investigators [10, 19] . These patients had significantly higher basal concentrations of serum calcitonin and CEA indicating larger tumor volume. This finding was confirmed by morphometric studies of lymph node metastases. Kwekkeboom et al. [20] had previously shown that small MTC tumors, although expressing sstr shown by autoradiography, were not always visualized scintigraphically. They could not decide whether this was due to small size of the lesion or to low density of sstr, or both. The growth rate of MTC can be monitored by measuring the increase of serum calcitonin with time [7, 21] . There is an evident relation between the increment of plasma calcitonin and bad prognosis and tumor recurrence [21] . In our own series, the annual increment of basal calcitonin levels was much higher in patients with scintigraphically positive tumors. This finding could be due to large tumor volume and/or expression of sstr in the rapidly growing tumors. In our series, tumor-associated symptoms and mortality [11] . These results are in contrast to the study performed by Kwekkeboom et al. [20] , in which the ratio between basal serum calcitonin and CEA concentrations were high in patients with positive imaging. They interpreted this finding that well-differentiated tumors expressed sstr, especially since one MTC tumor, previously studied in several tumoral regions by autoradiography, seemed to express sstr in the more differentiated parts.
In a previous study, we studied T/B ratios in several different scintigraphy-positive neuroendocrine tumors with large variations between tumor types: low values for MTC , high values for carcinoid tumors and sometimes very high values for endocrine pancreatic tumors (910-1500) [13, 22] . The T/B ratio seemed to be little influenced by the time interval between injection of I lIn-octreotide and surgery. This indicates Figure 3 . l1lln concentration ratio between tissue biopsies and blood (Ti/B), between tumor and adjacent tissue from scintigraphy (t/bg) and somatostatin receptor subtypes for patient C with bilateral papillary thyroid carcinoma with lymph node metastases, five days after injection of lllIn-DTPA-D-Phel-octreotide.
Histopathological
Ti similar pharmacokinetics II1n in tumor and non-tumor tissues, including blood, after the initial uptake phase [23] . In some studies using radiolabelled monoclonal antibodies on experimental tumors, a declining T/B ratio has been shown with increasing tumor size [24] . These findings have not been corroborated in patients with neuroendocrine tumors receiving IIIIn-DTPA-D-PheI-octreotide [13] A) . However, it is important to bear in mind that only half of the surgically found metastases were visualized in the receptor-positive patients [10, 11] , which means that the surgical exploration should be extended beyond the visualized sites. Visualization of lymph node metastases may also serve as an indicator of worse prognosis [11] .
Hurthle cell adenoma/carcinoma are thyroid tumors that cannot be visualized by 1311-or 99mTc scintigraphy. In our consecutive series of such patients (n = 6), both primary tumors and metastases were well demonstrated by Illln-DTPA-D-Phel-octreotide.
Patient B had a Hurthle cell adenoma in a nodular goitre, which illustrates a differential diagnostic problem. The Ti/B values of the goitre tissue approached that of the adenoma and was much higher than those seen in normal lymph nodes (Figure 2 ). The Ti/B values for the goitre tissue was much higher than that seen for normal thyroid tissue in patient C, also injected five days before surgery. The high uptake of II11n into the goitre tissue may represent cellular uptake not only into thyroid follicular cells, but also into lymphocytes infiltrating the sclerotic parts of the gland. A similar uptake of lllln in the thyroid in benign conditions (endemic goitre, thyroid autonomy and Graves' disease) has been reported previously [27] . The clinical management of this patient was not influenced by preoperative imaging studies.
There are only preliminary observations available on imaging by I1In-DTPA-DPhe1-octreotide in patients with thyroid carcinoma. Patient C with papillary thyroid cancer displayed intense uptake in the thyroid tumors (Figure 3) . No Metastases from Hurthle cell cancer and MTC can be visualized (i.e. tumor types that do not concentrate radioiodine) [10, 11, 28, 29] . 3. It has a complementary value to radioiodine scintigraphy in diagnosing metastases from papillary and follicular thyroid cancer [26] .
The future role of radiation therapy via sstr in patients with thyroid cancer and disseminated disease remains to be investigated.
